Diagreat RNA intelligent design and synthesis platform 
has the core technology of RNA chemical synthesis, 
which reaches the international leading level. We have a 
variety of services, including general siRNA synthesis, 
siRNA modification and labelling, siRNA design, miRNA 
design and synthesis, and common siRNA control which 
can meet the different scientific research needs of high 
quality customers.
—— siRNA ——
【Introduction】
Small interfering RNA(siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of 
double-stranded RNA molecules, 20-25 nucleotides in length, that play a variety of roles in biology. They are 
similar to miRNA, and works within the RNA interference(RNAi). siRNA interferes with the expression of 
specific genes with complementary nucleotide sequences by affecting the degradation of mRNA post-transcription, 
thus preventing translation. siRNA synthesis is the simplest and fastest method to achieve gene silencing in 
organism and cell. It has the advantages of high transfection efficiency with little toxicity, and large scale 
preparation. It is especially suitable for screening effective fragments of siRNA in the case of uncertain gene target 
sites. siRNA has irreplaceable advantages in gene function studies , drug target and drug screening.
【Advantages】
1.Professional project 
management team, 
comprehensive 
professional pre-sales 
consulting, order 
design and after-sales 
service.
2.ISO13485 strict quality 
control standards, GMP 
factory, and 
comprehensive quality 
control report(
HPLC/MS).
3.The synthetic 
specifications are 
flexible and diverse, 
and can be customized 
in batches.
4.Provide personalized 
customized service, 
such as special service 
and preferential 
package services, etc.
【Special Services】
1.siRNA Design and Synthesis
Based on the target gene name, 
sequence or GeneBank ID, etc, 
Dia-up will design siRNA free of 
charge to ensure that at least one pair 
can effectively inhibit the expression 
of target genes. It will be redesigned 
and synthesized for free, if the 
silencing effect is not achieved.
2.Modified or labeled siRNA 
synthesis
Various modified and labeled 
siRNA synthesis can be carried 
out according to customer 
requirements. Custom modified 
or labeled siRNA synthesis is 
also available.
3.siRNA screening
Dia-up provides effective siRNA 
screening services, helps 
customers screening out the most 
effective siRNA, and provides 
detailed experimental reports, 
including experimental methods, 
procedures, photos and relevant 
data.
【Single-gene Package】
Package A: Genral siRNA economical package
| Products | Quantity | Specification | Purification | 
| Target gene siRNA oligos | 3 pairs | 3*2OD | HPLC | 
| Negative control siRNA oligos | 1 pairs | 1*1OD | HPLC | 
| FAM labeled negative control | 1 pairs | 1*1OD | HPLC | 
| Positive control siRNA oligos | 1 pairs | 1*1OD | HPLC | 
Package B: Genral siRNA economical package
| Products | Quantity | Specification | Purification | 
| Target gene siRNA oligos | 4 pairs | 4*4OD | HPLC | 
| Negative control siRNA oligos | 1 pairs | 1*1OD | HPLC | 
| FAM labeled negative control | 1 pairs | 1*1OD | HPLC | 
| Positive control siRNA oligos | 1 pairs | 1*1OD | HPLC | 
Package C: Chemical modified siRNA economical package
| Products | Quantity | Specification | Purification | 
| Target gene siRNA oligos | 3pairs | 3*2OD | HPLC | 
| Negative control siRNA oligos | 1 pairs | 1*1OD | HPLC | 
| FAM labeled negative control | 1 pairs | 1*1OD | HPLC | 
| Positive control siRNA oligos | 1 pairs | 1*1OD | HPLC | 
Package D: Chemical modified siRNA affordable package
| Products | Quantity | Specification | Purification | 
| Target gene siRNA oligos | 4pairs | 4*4OD | HPLC | 
| Negative control siRNA oligos | 1 pairs | 1*1OD | HPLC | 
| FAM labeled negative control | 1 pairs | 1*1OD | HPLC | 
| Positive control siRNA oligos | 1 pairs | 1*1OD | HPLC | 
Package E: Fluorescent dye labeled siRNA economical package
| Products | Quantity | Specification | Purification | 
| Target gene siRNA oligos | 3pairs | 3*2OD | HPLC | 
| Negative control siRNA oligos | 1 pairs | 1*1OD | HPLC | 
| FAM labeled negative control | 1 pairs | 1*1OD | HPLC | 
| Positive control siRNA oligos | 1 pairs | 1*1OD | HPLC | 
Package F: Fluorescent dye labeled siRNA affordable package
| Products | Quantity | Specification | Purification | 
| Target gene siRNA oligos | 4pairs | 4*4OD | HPLC | 
| Negative control siRNA oligos | 1 pairs | 1*1OD | HPLC | 
| FAM labeled negative control | 1 pairs | 1*1OD | HPLC | 
| Positive control siRNA oligos | 1 pairs | 1*1OD | HPLC | 
【Service Procedure】

【Project Delivery Result】
【Order Information】
RNA Synthesis
| Product type | Specification | Product name | Delivery | 
| General siRNA | 2 OD | General siRNA synthesis | 5 working days | 
| 3 OD | 5 working days | 
| 4 OD | 5 working days | 
| 5 OD | 5 working days | 
| 6 OD | 5 working days | 
| 7 OD | 5 working days | 
| 8 OD | 5 working days | 
| 9 OD | 5 working days | 
| 10 OD | 5 working days | 
| 25 OD | 5 working days | 
| 50 OD | 5 working days | 
| 100 OD | 5 working days | 
| Above 250 OD | Upon request | 
| General siRNA package A | 3pairs(3X2 0D) 1pairs(1X1 0D) 1pairs(1X1 0D) 1pairs(1X1 0D) | Target gene siRNA oligos Negative control siRNA oligos FAM labeled negative control siRNA oligos Positive control siRNA oligo | 5 working days | 
| General siRNA package B | 4pairs(4X4 0D) 1pairs(1X1 0D) 1pairs(1X1 0D) 1pairs(1X1 0D) | Target gene siRNA oligos Negative control siRNA oligos FAM labeled negative control siRNA oligos Positive control siRNA oligo | 5 working days | 
| Product type | Specification | Product name | Delivery | 
| Chemical modified siRNA package 
C (thio, oligo, amino, sulfhydryl) | 3 pairs (3X2 OD 1 pair (1X1 OD)  1 pair (1X1 OD)  1 pair (1X1 OD)  | Target gene siRNA oligos Negative control siRNA oligos FAM labeled negative control siRNA oligos Positive control siRNA oligos 
 | 5 working days | 
| Chemical modified siRNA package
 D (thio, oligo, amino, sulfhydryl) | 4 pairs (4X4 OD 1 pair (1X1 OD) 1 pair (1X1 OD)  1 pair (1X1 OD) | Target gene siRNA oligos Negative control siRNA oligos FAM labeled negative control siRNA oligos Positive control siRNA oligos | 5 working days | 
| Fluorescent dye labeled siRNA 
package E (FAM, HEX, Cy3) | 3 pairs (3X2 OD) 1 pair (1X1 OD)  1 pair (1X1 OD)  1 pair (1X1 OD) | Target gene siRNA oligos Negative control siRNA oligos FAM labeled negative control siRNA oligos Positive control siRNA oligos | 5 working days | 
| Fluorescent dye labeled siRNA 
package F (FAM, HEX, Cy3) | 4 pairs (4X4 OD) 1 pair (1X1 OD)  1 pair (1X1 OD)  1 pair (1X1 OD) | Target gene siRNA oligos Negative control siRNA oligos FAM labeled negative control siRNA oligos Positive control siRNA oligos | 5 working days | 
| In vivo siRNA package G 
(Full chain methoxy modification, 
terminal cholesterol modification) | 3 pairs (3X2 OD)  1 pair (1X1 OD)  1 pair (1X1 OD)  1 pair (1X1 OD) | Target gene siRNA oligos Negative control siRNA oligos FAM labeled negative control siRNA oligos Positive control siRNA oligos | 8 working days | 
| In vivo siRNA package H
 (Full chain methoxy modification, 
terminal cholesterol modification) | 3  pairs (4X4 OD) 1 pair (1X1 OD)  1 pair (1X1 OD)  1 pair (1X1 OD) | Target gene siRNA oligos Negative control siRNA oligos FAM labeled negative control siRNA oligos Positive control siRNA oligos | 8 working days | 
| Fluorescent dye labeled siRNA | 4  OD 5  OD 10 OD 25 OD 50 OD 100 OD250 OD | Fluorescent dye 
labeled siRNA | 7 working days 7 working days  7 working days  11 working days  7 working days  16 working days  21 working days | 
RNA Modification Type
| Type | Modification marker | Purification | Type | Modification | Purification | 
| Rare base | dI rI m5rC m6rA 2'-0-MethylRNA 2'F RNA m7rG LNA-X mlrA m5Cm m5Um 
 | HPLC | Other modification | Spacer9 Azide DBCO Spacer(C6) Spacer9 Spacer(C12) Spacer C3 Spacer C18 dSpacer PL Int Amino dT Int Biotin dT Int Cy3 dT Int Cy5 dT Int TAMRA dT Int ROX dT Int FAM dT Int HEX dT Int Dig dT Int DBCO dT Int TAMRA dT Int ATTO Flour dT Int BHQ1 dT Int BHQ2 dT Int NPOM Dt | HPLC | 
| Thiomodification
(Phosphorothioates) | S | HPLC | NH2 modification
(Amino Linkers) | 5'Amino C6 3' Amino C7 | HPLC | 
| Phosphorylation | 5'PHO   3' PHO | HPLC | SH modification
(Thiol) | 3'Thiol C3 5'Thiol C6 | HPLC | 
| Biotin | 5'Biotin 3'Biotin TEG 5'Desthiobiotin 3'Desthiobiotin | HPLC | (Digoxigenin) | 5'DI G3' DIG | HPLC | 
| (Fluorescence) | 5' Cy3 3' Cy3 5’Cy5 3’Cy5 5’FAM 3’FAM 5’HEX 3’HEX 5’-FITC 3’-FITC 5’6-JOE 3’6-JOE 5’ROX 3’ROX 5’TAMRA 3’TAMRA 5’Texas Red 3’Texas Red 
 | HPLC | (Quenchers) | 3’DABCYL 3’TAMRA3' BHQ 1 3’BHQ 2 3’BHQ3 3’-MGB 3’TQ1-TQ7系列 3'eclipse | HPLC | 
| (Fluorescence) | 5'Quasar 570 3'Quasar 570 5'Quasar 670 3'Quasar 670 5'Cy5. 5NS 3' Cy5. 5NS 5'Cy7NS 3' Cy7NS 5'&3DABCYL 5'83'AMCA 5'-VIC | HPLC | 
Double Labeled Modification
| Type | Modification marker | Purification | Type | Modification | Purification | 
| TAMRA | 5’FAM-3’TAMRA 5’HEX-3’TAMRA 5’TET-3’TAMRA 5’JOE-3’TAMRA 5'  VIC-3'  TAMRA | HPLC | BHQ1 | 5’FAM-3’BHQ1 5’VIC-3’BHQ1 5’HEX-3’BHQ1 | HPLC | 
| ECLIPS | 5’FAM-3’ECLIPS 5’HEX-3’ECLIPS 5' TAMRA-3’Eclipse 5' ROX-3’Eclipse 5' TET-3’Eclipse 5' JOE-3’Eclipse5 | HPLC | MGB | 5’FAM-3' MGB 5’HEX-3' MGB 5’ROX-3' MGB 5’Texas Red-3’MGB 5’Quasar 670-3’MGB 5’ VIC-3’MGB | HPLC | 
| BHQ2 | 5' Cy5-3' BHQ2 5' Cy3-3' BHQ2 5' ROX-3' BHQ2 5' ROX-3' BHQ2 5' TET-3' BHQ2 5' JOE-3' BHQ2 5' HEX-3' BHQ2 5' TAMRA-3' BHQ2 5' Texas Red-3' BHQ2 5' Quasar 670-3' BHQ2 5' -FAM and 3' BHQ2 | HPLC | MGB | 5' FAM-3'MGB 5' HEX-3'MGB 5'ROX-3'MGB 5'Texas Red-3'MGB 5'Quasar 670-3'MGB 5' VIC-3'MGB | HPLC | 
| Dabcyl | 5' FAM-3' DABCYL 5' HEX-3' DABCYL 5' TAMRA-3' DABCYL 5'Texas Red-3'Dabcyl 5'ROX-3'Dabcyl 5'CY3-3'DABCYL 5' Cy5-3' DABCYL | HPLC | 
| Other 
double
labeled 
modification | 5' Cy5,3' SH 5' Dabcyl,3' C3-Fam 5' DlG,3' Digoxin 5' SH,3' Cy3 5' Fam,3' C3-Fam 5' TAMRA 3' C3-Fam 5' Cy5,3' C7-NH2 | HPLC | Other 
double
labeled 
modification | 5'Phos and 3'FAM 5'TAMRA and 3' Phos 5' C6-Biotin,3' Biotin 5' C6-Biotin,3' Cy5 5' C6-NH2,3' C3-Fam 5' C6-NH2,3' Cy3 5' Cy5,SS, | HPLC | 
| BHQ3 | 5' Quasar 670-3' BHQ3 5' CY5-3' BHQ3 | HPLC | 
 | 
 | 
 | 
* Other modification types upon request.
 —— miRNA —— 
MicroRNAs (miRNAs) are endogenous single-stranded RNAs of 18-25nt in eukaryotic organisms, which 
can regulate the complementary mRNAs at the post-transcriptional level through cleavage or translational 
repression of the mRNA targets.According to the recent studies, miRNA are involved in a variety of 
regulatory pathways, including development, viral defense, hematopoietic processes, organogenesis, cell 
proliferation, apoptosis, and fat metabolism. Dia-up’s advanced synthesis technology can provide customers 
with miRNA inhibitors, miRNA mimics, miRNA negative controls, Agomir and Antagomir.
【Unique Products】
miRNA inhibitors
Introduction
Advantages
Application
- the Loss-of-function effect can be further 
investigated with microRNA, which can reduce 
the miRNA activity by GMR-miRTM microRNA 
inhibitors inhibition 
- Screening for miRNAs that regulate the expression 
of a gene 
- Further study the function of miRNA in 
biological process, such as cell development, 
proliferation, differentiation and apoptosis. 
miRNA mimics
Introduction
Advantages
- convenient and efficient, can be transfected into 
cells and play a role. 
- The operation is simple and can be transfected into 
cells with transfection reagent withoutconstructing the 
vector, and the transfection efficiency can be studied t
hrough transfection control. 
- Short experiment period  
- Has a wide range of application 
Agomir and Antagomir
Introduction
- Agomir is specially labeled and chemically modified miRNA agonist. Agomir can regulate the biological function
of the target gene by mimicking endogenous microRNAs. 
- Antagomir, with a design that is based on the mature microRNA sequence, is chemically modified miRNA antagonist. 
Advantages
- Compared with common miRNA inhibitors and mimics, both Antagomir and Agomir have a higher affinity for the 
cell membrane. Therefore, the amount of transfection reagent could be drastically reduced. 
- Has a wide range of application, especially suitable for animals and cell experiment. 
- Easy to operate, and can be injected into the animal by method of intravenous or local injection. 
- The interfering effect can last a long time, at least one week. The longest interfering effect can be up 
to 5-6 weeks. 
- They can be enriched in target cells, inducing effective, specific and stable interfering effects. 
Application
Specific microRNA Agomir can be introduced into cells which express the corresponding microRNA, and then 
it simulates the effect of microRNA to simulate/inhibit the effect of microRNA. Or the specific microRNA 
Agomir/Antagomir can be used to combine with the double luciferase reporter system/suppress the expression of 
a reporter vector, to verify the regulatory relationship between the miRNA and the target gene.
【Advantages】
- Professional project 
management team, 
comprehensive 
professional pre-sales 
consulting, order 
design and after-sales 
service. 
- ISO13485 strict quality 
control standards, GMP 
factory, and 
comprehensive quality 
control report(
HPLC/MS). 
- The synthetic 
specifications are 
flexible and diverse, 
and can be customized 
in batches. 
- Provide personalized 
customized service, 
such as special service 
and preferential 
package services, etc. 
 
 
【Service Procedure】

【Project Delivery Result】
【Order Information】
| Product type | Specification | Product name | Delivery | 
| microRNA | 2OD | microRNA mimics microRNA inhibitor microRNA mimics N.C microRNA inhibitor N.C microRNA agomiR microRNA antagomiR microRNA agomiR N.C microRNA antagomiR N.C | 5 working days | 
【Unique Products】
Dia-up Biotech provides common RNA control for the convenience of all scientific customers.
All product ready to ship.
| Product type | Specification | Product name | 
| Control siRNA | 1 OD | Negative control siRNA FAM labeled negative control siRNA GAPDH positive control siRNA P53 positive control siRNA β-actin positive control siRNA Mimics N.C Inhibitor N.C | 
 —— mRNA —— 
mRNA synthesis for RNA vaccine and medicine R&D
